Hadly Clark is an associate director on the FasterCures team at Milken Institute Health. She is an experienced health care professional focused on the intersection of health and technology and leads oncology-focused initiatives exploring innovative screening technologies and anti-cancer treatments.
The rapid advancement of the health technology landscape relies heavily on patient data. Patient data from medical records and digital health apps can be leveraged to build new tools that can help diagnose disease, remotely monitor and track patients, and make groundbreaking discoveries that lead to new treatments and cures. Data-reliant entities, such as technology companies, have the most advanced capabilities to aggregate and analyze these data. But, because their activities fall outside of the traditional authority that governs health data privacy, their participation carries substantial implications for how patient data are collected and used.
The Pew Research Center, which publishes an annual survey to measure social trust, defines trust as a “belief in the honesty, integrity, and reliability of others—a ‘faith in people.’" The 2022 annual Edelman Trust Barometer found that distrust is the default for the majority of people. Fifty-nine percent of respondents indicate they tend to distrust until they see evidence that something is trustworthy versus a tendency to trust until they see evidence that something is untrustworthy. According to a poll of 2,200 adults across the country, fewer than three in five Americans trust the US health-care system. Further trust in the scientific, community has eroded since this tracking began in November 2020.
To move toward a system that patients trust, we must paint a clear picture of the desired system. In late 2020, FasterCures brought together experts who work with patient data in various settings to outline key elements of a trusted system. Part of the work was to envision the aspects needed to establish trust. Experts identified three foundational components of trust. For this report, we focus on one of the elements: the need to create strong and clear protections for patient data. The other two elements—ensuring that patients reap benefits from contributing their data and creating safe platforms and spaces for peer groups— are also crucial and will be addressed in our ongoing work.
Through significant advancements in biomedical innovation, new promising gene and cell therapy treatments may be the key to unlocking the cure to debilitating genetic, oncologic, and other diseases that were once deemed incurable. The first...
The United States—as of June 2020—has more reported cases of COVID-19 than any other country in the world, despite having many of the same resources as other countries that curbed the pandemic more successfully. COVID-19 has highlighted the...
If the objective of biomedical research is to spur innovation to create healthier communities, extend life, and more effectively treat or cure disease, then persistent inequities run counter to that goal and create unnecessary barriers to...
New blood-based technologies, known as multi-cancer early detection (MCED) tests, are entering the market and can identify multiple cancers early and simultaneously. These tests detect signals found in DNA that cancer cells shed into the...
Technological innovation in the health landscape is occurring rapidly, and much of it would not be possible without patient data. Health data sets can be leveraged to build new tools that can help diagnose disease, remotely monitor and...
The fuel for biomedical innovation is data. Data-driven patient participation — or patient contribution of their biospecimens, self-reported or wearable data, health record data, and other information — has emerged as a tool that may help...
In 2022, FasterCures published a report titled The Current Landscape of the Science of Patient Input, which examined the progress of patient engagement (PE) in biomedical research and identified ways to overcome ongoing challenges. Building...
Patient preferences and insights are increasingly considered throughout the medical product life cycle in addition to clinical outcomes. We know that incorporating patient preferences in the product life cycle can create meaningful results...
Patient preferences and insights are increasingly considered throughout the medical product life cycle in addition to clinical outcomes. We know that incorporating patient preferences in the product...
The 26th annual Milken Institute Global Conference convened the best minds in the world to tackle its most urgent challenges and realize its most exciting opportunities. Throughout the four-day event, our health teams curated nearly three...